North America Biopsy Devices Market Industry: Market Size & Forecast 2026

The North America Biopsy Devices Market covers equipment used to obtain tissue or cell samples for pathological examination, a critical step in diagnosing cancers and other conditions. The market encompasses needle-based biopsy systems, localization wires, biopsy guns, vacuum-assisted devices, and procedure trays, valued at approximately $2.56 billion in 2025 with projected compound annual growth of 5.0%. Products are guided by imaging technologies including ultrasound, CT scans, and stereotactic systems to improve targeting accuracy.

• •Needle-based biopsy systems represent the largest product segment, followed by vacuum-assisted and biopsy gun categories.
• •Imaging guidance technologies, ultrasound-guided, stereotactic-guided, and CT-guided biopsy, are essential sub-segments influencing device selection.
• •The market spans the United States, Canada, and Mexico, with the U.S. accounting for the predominant share of regional revenue.

Rising cancer prevalence across North America is the primary market catalyst, with biopsies remaining the gold standard for definitive diagnosis. The aging Baby Boomer population, increased cancer screening awareness, and technological improvements in minimally invasive techniques are collectively expanding procedural volumes. Government incentives supporting cancer diagnostics and strategic partnerships between device manufacturers and healthcare institutions are further accelerating market adoption.

• •Increasing incidence of breast, lung, prostate, and colorectal cancers sustains procedural demand across the region.
• •Technological advancements in imaging-guided and vacuum-assisted biopsy systems enable smaller incisions, faster recovery, and improved diagnostic yield.
• •Government initiatives promoting early cancer detection and reimbursement policies favorable to advanced biopsy techniques support market expansion.

The market is segmented by product into needle-based biopsy devices, localization wires, and procedure trays, with needle-based systems commanding the largest revenue share. By technology, the market is categorized into ultrasound-guided, stereotactic-guided, CT scan-guided, and MRI-guided biopsy systems, each serving distinct clinical applications. The United States leads regionally due to superior healthcare infrastructure, higher healthcare spending, and broader insurance coverage for advanced biopsy procedures, while Canada and Mexico represent smaller but growing segments.

• •Needle-based biopsy devices constitute the dominant product category, with vacuum-assisted needle devices representing a high-growth sub-segment.
• •Ultrasound-guided biopsy holds the largest technology share, while MRI-guided and stereotactic systems grow fastest due to precision advantages.
• •The U.S. market benefits from advanced hospital networks and favorable reimbursement, while Canada and Mexico are expanding through healthcare modernization initiatives.

What are the recent trends and outlook?

Key trends shaping the market include increasing adoption of vacuum-assisted biopsy devices, which yield larger and higher-quality tissue samples, and growing use of MRI-guided biopsy for detecting lesions not visible on mammography or ultrasound. Integration of artificial intelligence and machine learning with imaging systems is enhancing lesion targeting accuracy and reducing procedure times. The market is expected to sustain steady growth through 2033, supported by an aging population, expanded cancer screening programs, and ongoing government backing for diagnostic innovation.

• •Minimally invasive techniques are gaining preference over surgical biopsies, driving demand for advanced needle-based and vacuum-assisted systems.
• •AI-assisted imaging guidance and robotic-assisted biopsy technologies are emerging as innovation frontiers with potential to improve clinical outcomes.
• •Government support for cancer diagnostics infrastructure, combined with rising preventive healthcare awareness, positions the market for sustained expansion through the early 2030s.